Skip to main content
KANGSTEM BIOTECH CO., LTD. logo

KANGSTEM BIOTECH CO., LTD. — Investor Relations & Filings

Ticker · 217730 ISIN · KR7217730001 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2021-03-25 Declaration of Voting R…
Country KR South Korea
Listing KO 217730

About KANGSTEM BIOTECH CO., LTD.

https://kangstem.com

KANGSTEM BIOTECH CO., LTD. is a biopharmaceutical company that researches and develops advanced stem cell therapies. The company focuses on creating treatments for rare, incurable, and autoimmune diseases, with a pipeline that includes therapeutic candidates for neurological disorders. Leveraging proprietary technologies for the isolation and mass culture of mesenchymal stem cells, Kangstem Biotech also develops and commercializes stem cell culture media and related cosmetic products. The company is dedicated to addressing unmet medical needs through the development of next-generation biopharmaceuticals.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the voting outcomes for various agenda items (financial statement approval, director/auditor appointments, business purpose changes, etc.) held on March 25, 2021. This document directly reports the official results of shareholder voting at the AGM, which aligns perfectly with the definition for 'Declaration of Voting Results & Voting Rights Announcements'.
2021-03-25 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding the change of the company's CEO (Representative Director). It details the outgoing CEO, the incoming CEO (Na Jong-cheon), the reason for the change, the date of the board resolution, and the professional background of the new appointee. This falls directly under the category of Board/Management Information.
2021-03-25 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to directors and employees, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and equity-based compensation falls under the category of 'Share Issue/Capital Change' (SHA) within the provided classification schema.
2021-03-25 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This document details the acquisition of shares by a company executive (Lee Tae Wha of Kangstem Biotech). According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing'.
2021-03-17 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by Kangstem Biotech. It contains the auditor's opinion (적정 - unqualified), financial highlights (assets, liabilities, equity, profit/loss), and details regarding the audit process. While it provides financial data, it is a regulatory filing specifically announcing the submission of the audit report to the exchange, which fits the 'Audit Report / Information' (AR) category as it provides the audit results and financial summary. FY 2020
2021-03-17 Korean
사업보고서 (2020.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Kangstem Biotech, covering the fiscal year 2020. It includes the independent auditor's opinion, consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, and Statement of Cash Flows), and detailed notes. It is not an Annual Report (10-K) as it lacks the broader management discussion and analysis (MD&A) and business overview typically found in a full 10-K, and it is not an announcement (RPA) because it contains the full financial data and audit opinion. FY 2020
2021-03-17 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.